Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neuraxis, Inc.

1.80
+0.195012.19%
Volume:48.20K
Turnover:84.14K
Market Cap:12.95M
PE:-1.47
High:1.85
Open:1.58
Low:1.55
Close:1.60
Loading ...

NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025

GlobeNewswire
·
15 Apr

NeurAxis Stock Gains Post Q4 Earnings and Revenue Growth

Zacks
·
24 Mar

NeurAxis, Inc. Reports Strong Q4 Growth Amid Challenges

TIPRANKS
·
22 Mar

NeurAxis, Inc. Reports Strong Q4 2024 Results

TIPRANKS
·
21 Mar

Neuraxis reports Q4 revenue $761,000 vs. $531,000 last year

TIPRANKS
·
20 Mar

Neuraxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues

THOMSON REUTERS
·
20 Mar

Press Release: NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues

Dow Jones
·
20 Mar

Neuraxis Q4 EPS $(0.23) Up From $(0.85) YoY, Sales $761.16K Up From $531.46K YoY

Benzinga
·
20 Mar

NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States

GlobeNewswire
·
21 Jan

Neuraxis issues letter to shareholders

TIPRANKS
·
13 Jan

Press Release: NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year

Dow Jones
·
08 Jan

Neuraxis files $25M mixed securities shelf

TIPRANKS
·
14 Dec 2024

Neuraxis files to sell 6.57M shares of common stock for holders

TIPRANKS
·
14 Dec 2024

Neuraxis Inc Files for Mixed Shelf of up to $25 Mln – SEC Filing

THOMSON REUTERS
·
14 Dec 2024

Neuraxis Inc: Selling Stockholders May Offer and Sell up to 6.6 Mln Shares of Common Stock

THOMSON REUTERS
·
14 Dec 2024

Neuraxis Inc. Announces FDA 510(K) Clearance of Red for Testing and Evaluation of Patients With Chronic Constipation

THOMSON REUTERS
·
10 Dec 2024

Neuraxis Inc: Will Begin Process of Commercially Marketing Red and Expects Initial Revenues in 1Q25

THOMSON REUTERS
·
10 Dec 2024

NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation

GlobeNewswire
·
10 Dec 2024

BRIEF-Rosalind Advisors, Inc. Reports 9.9% Stake In Neuraxis Inc As Of November 12- SEC Filing

Reuters
·
03 Dec 2024

Rosalind Advisors, Inc. Reports 9.9% Stake in Neuraxis Inc as of November 12- SEC Filing

THOMSON REUTERS
·
03 Dec 2024